Copyright Reports & Markets. All rights reserved.

Global Myelofibrosis Drug Market 2023 by Manufacturers, Regions, Type and Application, Forecast to 2029

Request for Sample of this report
Buy now

1 Market Overview

  • 1.1 Product Overview and Scope of Myelofibrosis Drug
  • 1.2 Market Estimation Caveats and Base Year
  • 1.3 Market Analysis by Type
    • 1.3.1 Overview: Global Myelofibrosis Drug Consumption Value by Type: 2018 Versus 2022 Versus 2029
    • 1.3.2 JAK 1
    • 1.3.3 JAK 2
    • 1.3.4 Others
  • 1.4 Market Analysis by Application
    • 1.4.1 Overview: Global Myelofibrosis Drug Consumption Value by Application: 2018 Versus 2022 Versus 2029
    • 1.4.2 Primary Myelofibrosis
    • 1.4.3 Secondary Myelofibrosis
  • 1.5 Global Myelofibrosis Drug Market Size & Forecast
    • 1.5.1 Global Myelofibrosis Drug Consumption Value (2018 & 2022 & 2029)
    • 1.5.2 Global Myelofibrosis Drug Sales Quantity (2018-2029)
    • 1.5.3 Global Myelofibrosis Drug Average Price (2018-2029)

2 Manufacturers Profiles

  • 2.1 GSK
    • 2.1.1 GSK Details
    • 2.1.2 GSK Major Business
    • 2.1.3 GSK Myelofibrosis Drug Product and Services
    • 2.1.4 GSK Myelofibrosis Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
    • 2.1.5 GSK Recent Developments/Updates
  • 2.2 AbbVie
    • 2.2.1 AbbVie Details
    • 2.2.2 AbbVie Major Business
    • 2.2.3 AbbVie Myelofibrosis Drug Product and Services
    • 2.2.4 AbbVie Myelofibrosis Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
    • 2.2.5 AbbVie Recent Developments/Updates
  • 2.3 Novartis
    • 2.3.1 Novartis Details
    • 2.3.2 Novartis Major Business
    • 2.3.3 Novartis Myelofibrosis Drug Product and Services
    • 2.3.4 Novartis Myelofibrosis Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
    • 2.3.5 Novartis Recent Developments/Updates
  • 2.4 Celgene
    • 2.4.1 Celgene Details
    • 2.4.2 Celgene Major Business
    • 2.4.3 Celgene Myelofibrosis Drug Product and Services
    • 2.4.4 Celgene Myelofibrosis Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
    • 2.4.5 Celgene Recent Developments/Updates
  • 2.5 Grunenthal
    • 2.5.1 Grunenthal Details
    • 2.5.2 Grunenthal Major Business
    • 2.5.3 Grunenthal Myelofibrosis Drug Product and Services
    • 2.5.4 Grunenthal Myelofibrosis Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
    • 2.5.5 Grunenthal Recent Developments/Updates
  • 2.6 Incyte
    • 2.6.1 Incyte Details
    • 2.6.2 Incyte Major Business
    • 2.6.3 Incyte Myelofibrosis Drug Product and Services
    • 2.6.4 Incyte Myelofibrosis Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
    • 2.6.5 Incyte Recent Developments/Updates
  • 2.7 CTI BioPharma
    • 2.7.1 CTI BioPharma Details
    • 2.7.2 CTI BioPharma Major Business
    • 2.7.3 CTI BioPharma Myelofibrosis Drug Product and Services
    • 2.7.4 CTI BioPharma Myelofibrosis Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
    • 2.7.5 CTI BioPharma Recent Developments/Updates
  • 2.8 Bristol Myers Squibb
    • 2.8.1 Bristol Myers Squibb Details
    • 2.8.2 Bristol Myers Squibb Major Business
    • 2.8.3 Bristol Myers Squibb Myelofibrosis Drug Product and Services
    • 2.8.4 Bristol Myers Squibb Myelofibrosis Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
    • 2.8.5 Bristol Myers Squibb Recent Developments/Updates
  • 2.9 Suzhou Zelgen Biopharmaceuticals
    • 2.9.1 Suzhou Zelgen Biopharmaceuticals Details
    • 2.9.2 Suzhou Zelgen Biopharmaceuticals Major Business
    • 2.9.3 Suzhou Zelgen Biopharmaceuticals Myelofibrosis Drug Product and Services
    • 2.9.4 Suzhou Zelgen Biopharmaceuticals Myelofibrosis Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
    • 2.9.5 Suzhou Zelgen Biopharmaceuticals Recent Developments/Updates

3 Competitive Environment: Myelofibrosis Drug by Manufacturer

  • 3.1 Global Myelofibrosis Drug Sales Quantity by Manufacturer (2018-2023)
  • 3.2 Global Myelofibrosis Drug Revenue by Manufacturer (2018-2023)
  • 3.3 Global Myelofibrosis Drug Average Price by Manufacturer (2018-2023)
  • 3.4 Market Share Analysis (2022)
    • 3.4.1 Producer Shipments of Myelofibrosis Drug by Manufacturer Revenue ($MM) and Market Share (%): 2022
    • 3.4.2 Top 3 Myelofibrosis Drug Manufacturer Market Share in 2022
    • 3.4.2 Top 6 Myelofibrosis Drug Manufacturer Market Share in 2022
  • 3.5 Myelofibrosis Drug Market: Overall Company Footprint Analysis
    • 3.5.1 Myelofibrosis Drug Market: Region Footprint
    • 3.5.2 Myelofibrosis Drug Market: Company Product Type Footprint
    • 3.5.3 Myelofibrosis Drug Market: Company Product Application Footprint
  • 3.6 New Market Entrants and Barriers to Market Entry
  • 3.7 Mergers, Acquisition, Agreements, and Collaborations

4 Consumption Analysis by Region

  • 4.1 Global Myelofibrosis Drug Market Size by Region
    • 4.1.1 Global Myelofibrosis Drug Sales Quantity by Region (2018-2029)
    • 4.1.2 Global Myelofibrosis Drug Consumption Value by Region (2018-2029)
    • 4.1.3 Global Myelofibrosis Drug Average Price by Region (2018-2029)
  • 4.2 North America Myelofibrosis Drug Consumption Value (2018-2029)
  • 4.3 Europe Myelofibrosis Drug Consumption Value (2018-2029)
  • 4.4 Asia-Pacific Myelofibrosis Drug Consumption Value (2018-2029)
  • 4.5 South America Myelofibrosis Drug Consumption Value (2018-2029)
  • 4.6 Middle East and Africa Myelofibrosis Drug Consumption Value (2018-2029)

5 Market Segment by Type

  • 5.1 Global Myelofibrosis Drug Sales Quantity by Type (2018-2029)
  • 5.2 Global Myelofibrosis Drug Consumption Value by Type (2018-2029)
  • 5.3 Global Myelofibrosis Drug Average Price by Type (2018-2029)

6 Market Segment by Application

  • 6.1 Global Myelofibrosis Drug Sales Quantity by Application (2018-2029)
  • 6.2 Global Myelofibrosis Drug Consumption Value by Application (2018-2029)
  • 6.3 Global Myelofibrosis Drug Average Price by Application (2018-2029)

7 North America

  • 7.1 North America Myelofibrosis Drug Sales Quantity by Type (2018-2029)
  • 7.2 North America Myelofibrosis Drug Sales Quantity by Application (2018-2029)
  • 7.3 North America Myelofibrosis Drug Market Size by Country
    • 7.3.1 North America Myelofibrosis Drug Sales Quantity by Country (2018-2029)
    • 7.3.2 North America Myelofibrosis Drug Consumption Value by Country (2018-2029)
    • 7.3.3 United States Market Size and Forecast (2018-2029)
    • 7.3.4 Canada Market Size and Forecast (2018-2029)
    • 7.3.5 Mexico Market Size and Forecast (2018-2029)

8 Europe

  • 8.1 Europe Myelofibrosis Drug Sales Quantity by Type (2018-2029)
  • 8.2 Europe Myelofibrosis Drug Sales Quantity by Application (2018-2029)
  • 8.3 Europe Myelofibrosis Drug Market Size by Country
    • 8.3.1 Europe Myelofibrosis Drug Sales Quantity by Country (2018-2029)
    • 8.3.2 Europe Myelofibrosis Drug Consumption Value by Country (2018-2029)
    • 8.3.3 Germany Market Size and Forecast (2018-2029)
    • 8.3.4 France Market Size and Forecast (2018-2029)
    • 8.3.5 United Kingdom Market Size and Forecast (2018-2029)
    • 8.3.6 Russia Market Size and Forecast (2018-2029)
    • 8.3.7 Italy Market Size and Forecast (2018-2029)

9 Asia-Pacific

  • 9.1 Asia-Pacific Myelofibrosis Drug Sales Quantity by Type (2018-2029)
  • 9.2 Asia-Pacific Myelofibrosis Drug Sales Quantity by Application (2018-2029)
  • 9.3 Asia-Pacific Myelofibrosis Drug Market Size by Region
    • 9.3.1 Asia-Pacific Myelofibrosis Drug Sales Quantity by Region (2018-2029)
    • 9.3.2 Asia-Pacific Myelofibrosis Drug Consumption Value by Region (2018-2029)
    • 9.3.3 China Market Size and Forecast (2018-2029)
    • 9.3.4 Japan Market Size and Forecast (2018-2029)
    • 9.3.5 Korea Market Size and Forecast (2018-2029)
    • 9.3.6 India Market Size and Forecast (2018-2029)
    • 9.3.7 Southeast Asia Market Size and Forecast (2018-2029)
    • 9.3.8 Australia Market Size and Forecast (2018-2029)

10 South America

  • 10.1 South America Myelofibrosis Drug Sales Quantity by Type (2018-2029)
  • 10.2 South America Myelofibrosis Drug Sales Quantity by Application (2018-2029)
  • 10.3 South America Myelofibrosis Drug Market Size by Country
    • 10.3.1 South America Myelofibrosis Drug Sales Quantity by Country (2018-2029)
    • 10.3.2 South America Myelofibrosis Drug Consumption Value by Country (2018-2029)
    • 10.3.3 Brazil Market Size and Forecast (2018-2029)
    • 10.3.4 Argentina Market Size and Forecast (2018-2029)

11 Middle East & Africa

  • 11.1 Middle East & Africa Myelofibrosis Drug Sales Quantity by Type (2018-2029)
  • 11.2 Middle East & Africa Myelofibrosis Drug Sales Quantity by Application (2018-2029)
  • 11.3 Middle East & Africa Myelofibrosis Drug Market Size by Country
    • 11.3.1 Middle East & Africa Myelofibrosis Drug Sales Quantity by Country (2018-2029)
    • 11.3.2 Middle East & Africa Myelofibrosis Drug Consumption Value by Country (2018-2029)
    • 11.3.3 Turkey Market Size and Forecast (2018-2029)
    • 11.3.4 Egypt Market Size and Forecast (2018-2029)
    • 11.3.5 Saudi Arabia Market Size and Forecast (2018-2029)
    • 11.3.6 South Africa Market Size and Forecast (2018-2029)

12 Market Dynamics

  • 12.1 Myelofibrosis Drug Market Drivers
  • 12.2 Myelofibrosis Drug Market Restraints
  • 12.3 Myelofibrosis Drug Trends Analysis
  • 12.4 Porters Five Forces Analysis
    • 12.4.1 Threat of New Entrants
    • 12.4.2 Bargaining Power of Suppliers
    • 12.4.3 Bargaining Power of Buyers
    • 12.4.4 Threat of Substitutes
    • 12.4.5 Competitive Rivalry
  • 12.5 Influence of COVID-19 and Russia-Ukraine War
    • 12.5.1 Influence of COVID-19
    • 12.5.2 Influence of Russia-Ukraine War

13 Raw Material and Industry Chain

  • 13.1 Raw Material of Myelofibrosis Drug and Key Manufacturers
  • 13.2 Manufacturing Costs Percentage of Myelofibrosis Drug
  • 13.3 Myelofibrosis Drug Production Process
  • 13.4 Myelofibrosis Drug Industrial Chain

14 Shipments by Distribution Channel

  • 14.1 Sales Channel
    • 14.1.1 Direct to End-User
    • 14.1.2 Distributors
  • 14.2 Myelofibrosis Drug Typical Distributors
  • 14.3 Myelofibrosis Drug Typical Customers

15 Research Findings and Conclusion

    16 Appendix

    • 16.1 Methodology
    • 16.2 Research Process and Data Source

    According to our (Global Info Research) latest study, the global Myelofibrosis Drug market size was valued at USD million in 2022 and is forecast to a readjusted size of USD million by 2029 with a CAGR of % during review period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
    Myelofibrosis is an uncommon type of bone marrow cancer that disrupts your body's normal production of blood cells. Myelofibrosis causes extensive scarring in your bone marrow, leading to severe anemia that can cause weakness and fatigue.
    This report is a detailed and comprehensive analysis for global Myelofibrosis Drug market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2023, are provided.
    Key Features:
    Global Myelofibrosis Drug market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2018-2029
    Global Myelofibrosis Drug market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2018-2029
    Global Myelofibrosis Drug market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2018-2029
    Global Myelofibrosis Drug market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (US$/Unit), 2018-2023
    The Primary Objectives in This Report Are:
    To determine the size of the total market opportunity of global and key countries
    To assess the growth potential for Myelofibrosis Drug
    To forecast future growth in each product and end-use market
    To assess competitive factors affecting the marketplace
    This report profiles key players in the global Myelofibrosis Drug market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include GSK, AbbVie, Novartis, Celgene and Grunenthal, etc.
    This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.
    Market Segmentation
    Myelofibrosis Drug market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
    Market segment by Type
    JAK 1
    JAK 2
    Others
    Market segment by Application
    Primary Myelofibrosis
    Secondary Myelofibrosis
    Major players covered
    GSK
    AbbVie
    Novartis
    Celgene
    Grunenthal
    Incyte
    CTI BioPharma
    Bristol Myers Squibb
    Suzhou Zelgen Biopharmaceuticals
    Market segment by region, regional analysis covers
    North America (United States, Canada and Mexico)
    Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
    Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
    South America (Brazil, Argentina, Colombia, and Rest of South America)
    Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
    The content of the study subjects, includes a total of 15 chapters:
    Chapter 1, to describe Myelofibrosis Drug product scope, market overview, market estimation caveats and base year.
    Chapter 2, to profile the top manufacturers of Myelofibrosis Drug, with price, sales, revenue and global market share of Myelofibrosis Drug from 2018 to 2023.
    Chapter 3, the Myelofibrosis Drug competitive situation, sales quantity, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
    Chapter 4, the Myelofibrosis Drug breakdown data are shown at the regional level, to show the sales quantity, consumption value and growth by regions, from 2018 to 2029.
    Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2018 to 2029.
    Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value and market share for key countries in the world, from 2017 to 2022.and Myelofibrosis Drug market forecast, by regions, type and application, with sales and revenue, from 2024 to 2029.
    Chapter 12, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War.
    Chapter 13, the key raw materials and key suppliers, and industry chain of Myelofibrosis Drug.
    Chapter 14 and 15, to describe Myelofibrosis Drug sales channel, distributors, customers, research findings and conclusion.

    Buy now